Primary endpoint of the expansion cohorts phase
death
DISEASE PROGRESSION
Efficacy will be evaluated using the 6-month PFS. PFS is defined as the time from inclusion to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1 and iRECIST, or death from any cause, whichever occurs first. It will be evaluated at 6 months.